All In Biotech

Drug Trial Radar · NCT06451588

Fecal Microbiota Transplantation in Axial Spondyloarthritis

Donor Versus Autologous Fecal Microbiota Transplantation for Axial Spondyloarthritis: a Double Blind, Placebo-Controlled, Randomized Trial

Last checked: Nov 20, 2026Latest source record: Aug 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

99

Planned (sponsor's estimate)

Start

Jun 1, 2024

Primary completion

May 2027

Study completion Nov 2027

Sponsor

Lead sponsor
University Hospital of North NorwayAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Helse Nord
First posted
Jun 11, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Although biologic therapy have revolutionized the treatment of Spondyloarthrtitis (SpA), many patients do not experience complete relief of SpA related complaints. It has been established that patients with SpA have an altered composition of microorganisms (microbiota) in the gut compared to healthy controls, and that this correlates to disease activity and respons to therapy. The goal of this randomized double-blind study is to evaluate the efficacy of fecal microbiota transplantation (FMT) in patients with axial SpA with a suboptimal effect of biologic therapy. The main questions it aims to answer are: * Can FMT reduce disease activity in axial SpA? * Can FMT alleviate pain and reduce fatigue in axial SpA? * Is the composition of microorganisms restored to normal in patients with SpA after a treatment with FMT? Participants will receive a single treatment in the form of an enema with either donor FMT or placebo at baseline. The primary endpoint will be evaluated after 90 days, but efficacy and safety will be monitored from baseline until 365 days.

Conditions

  • Axial Spondyloarthritis
  • Ankylosing Spondylitis
  • Dysbiosis
  • Spondyloarthritis
  • Spondylitis
  • Arthritis
  • Musculoskeletal Diseases
  • Spinal Disease
  • Joint Diseases

Interventions

  • FMTDrug

    Active FMT

  • PlaceboDrug

    The placebo treatment will be prepared based on the patients' fecal samples (autologous).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Minimal Clinically Important ImprovementTime frame: 90 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University Hospital North Norway

    Tromsø, Norway · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.